Checkpoint Inhibitor denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Checkpoint Inhibitors for Medical Necessity

Cigna's medical-necessity denials for checkpoint inhibitors arise when the clinical documentation submitted with the prior authorization or claim does not clearly establish that the patient's cancer type, biomarker profile, treatment history, and performance status meet all of Cigna's coverage criteria for the specific agent and indication. Cigna applies its own Coverage Policy, which draws on the FDA-approved labeling and recognized oncology guideline organizations. Reviewers look for precise, documented answers to each criterion — and when those answers are missing, incomplete, or buried in chart notes rather than clearly stated, a denial follows even when the drug is clinically appropriate.

## Why This Denial Is Appealable

Medical-necessity denials are adverse benefit determinations with full appeal rights under ACA §2719 and ERISA §503. Oncology cases frequently qualify for the expedited review track, which resolves within 72 hours, because delay in cancer treatment can cause serious harm. If the internal appeal is unsuccessful, you have the right to independent external review by an IRO with oncology expertise; this window is typically 4 months from the final internal denial. External review reversal rates for oncology medical-necessity denials are among the highest of any therapeutic area when appeals are properly documented.

## The Appeal Process

1. Obtain Cigna's Coverage Policy for the specific checkpoint inhibitor prescribed — the exact criteria are published and must be provided to you on request. 2. Compare the coverage criteria against the existing medical record and identify every gap. 3. Have the treating oncologist generate documentation that fills each gap directly and explicitly. 4. File a written internal appeal; request a peer-to-peer review between the treating oncologist and Cigna's medical director. 5. If denied, file for external review immediately.

## Documentation to Gather

• Pathology and molecular profiling: Tumor type, histology, and any biomarker or receptor testing results relevant to the FDA-approved indication for the prescribed agent.
• Staging and disease-extent documentation: Imaging, surgical, or other records confirming disease stage and extent.
• Prior treatment history: A chronological list of prior systemic therapies with dates, responses or lack thereof, and reasons for discontinuation.
• Performance status and clinical condition: ECOG or equivalent functional status documentation from recent clinic visits.
• Oncologist's medical-necessity letter: Mapping each Cigna criterion to a specific chart finding, referencing the applicable guideline organization's recommendation and the FDA label.

## Criteria-Mapping Structure

Copy each requirement from Cigna's Coverage Policy into a structured table. In the adjacent column, cite the exact chart entry, test result, or note date that satisfies it. Do not leave any criterion unanswered. The appeal letter should include this mapping as a central organizing element — it transforms a narrative argument into a compliance checklist that reviewers can verify rapidly.